Policy Developments - The National Medical Products Administration (NMPA) is optimizing the review and approval process for urgently needed overseas drugs that have already been marketed, aiming to meet the pressing clinical needs of patients [1] Drug and Device Approvals - Yifan Pharmaceutical's subsidiary received a registration acceptance notice for Yihuang Decoction Granules, which is indicated for kidney strengthening and dampness clearing [2] - Zhenghai Bio announced that it received a medical device registration acceptance notice for a uterine cavity repair membrane, currently in the acceptance stage [3] - Microchip Biotech's Xidabendan Tablets have been approved for sale in Macau, marking an expansion into overseas markets [4] - Heng Rui Medicine's innovative drug Ruirafulpu α injection has been approved for marketing, with no similar products currently approved domestically or internationally, and a cumulative R&D investment of approximately 711 million yuan [5] Capital Market Insights - Bibet reported that it is not yet profitable and has accumulated unremedied losses, with only one product approved and several others in various clinical trial stages, indicating a need for significant ongoing R&D investment [6] - Innovation Medical confirmed that its production and operational status is normal, with no undisclosed significant matters [7][8] Industry Events - Yiming Onco announced the termination of its collaboration agreement with Axion Bio, regaining global development and commercialization rights for two core anti-cancer drugs, with previously received payments unaffected [9] Public Opinion Alerts - The Director of the Jiangxi Provincial Health Commission is under disciplinary review and investigation for serious violations of discipline and law [10]

Core Viewpoint - The National Medical Products Administration (NMPA) of China is optimizing the review and approval process for urgently needed foreign drugs already on the market to meet the pressing clinical needs of patients [1][2]. Group 1: Review and Approval Process - The NMPA encourages applicants to conduct global synchronized research and simultaneous applications for urgently needed foreign drugs, including both original and generic drugs, which may qualify for priority review and approval [1]. - The review mechanism is being optimized to accelerate the approval speed, allowing applicants to utilize clinical data from both domestic and foreign sources, and submit necessary supporting materials for urgent clinical needs [2]. - Drugs that are included in the priority review and approval category will be managed separately by the Drug Review Center, with enhanced communication and guidance [3]. Group 2: Inspection and Registration - For rare disease drugs that are urgently needed but not yet available in China, applicants are encouraged to apply for registration inspection using a pre-inspection method, reducing the inspection time from 60 days to 40 days for sample inspections [3]. - The registration inspection timeline is also shortened from 90 days to 70 days when both standard review and sample inspection are conducted simultaneously [3]. - The NMPA is optimizing the registration verification process by integrating risk-based approaches to determine the method of inspection, whether on-site or remote [3]. Group 3: Import Channels - The NMPA is committed to maintaining a smooth temporary import channel for urgently needed drugs, particularly for rare diseases, to enhance efficiency and meet the clinical needs of medical institutions [3].